Abbas D, et al. Acceptability of an outpatient regimen of medical abortion with mifepristone and 800 mcg misoprostol administered buccally or sublingually at 71-84 days of gestation: a series of exploratory studies. Contraception. 2014 May;89(5):480.

Aiken ARA, Digol I, Trussel J, Gomperts R. Self Reported Outcomes and Adverse Events After Medical Abortion Through Online Telemedicine: Population Based Study in the Republic of Ireland and Northern Ireland. BMJ. 2017 May 16;357:j2011.

Ashok, PW, Penney GC, Flett GMM, Templeton, A. An effective Regimen for Early Medical Abortion:  A Report of 200 Consecutive Cases. Hum Reprod 1998;13:2962-2965.

Blum J, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118:166-71.

Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao. Eur J Contracept Reprod Health Care. 2011 Apr;16(2):61-6.

Bracken H, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone–misoprostol. BJOG. 2011;118(1):17-23.

Bracken H, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective open-label trial. Contraception. 2014 Mar;89(3):181-6.

Brandi K, Woodhams E, White K O, Mehta P K. An exploration of perceived contraceptive coercion at the time of abortion. Contraception. 2018 Apr;97(4):329-334.

Castillo P, et al. Does a repeat dose of 800 mcg misoprostol following mifepristone improve outcomes in the later first trimester?. In: 41st Annual NAF Meeting 2017, Montreal, Canada.

Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-5.

Chen MJ, Creinin MD. Mifepristone with Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol. 2015 Jul;126(1):12-21.

Chong E, et al. A Prospective, Non-Randomized Study of Home Use of Mifepristone for Medical Abortion in the U.S. Contraception. 2015 Sep;92(3):215-9.

Clark W, et al. Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. Contraception. 2007 Feb;75(2):131-5.

Creinin MD, et al.  A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion.  Obstet Gynecol 2004 May;103(5 Pt 1):851-859.

Creinin MD, et al. Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial. Obstet Gynecol. 2020 Jan; 135(1):158-165.

Colwill AC, Bayer LL, Bednarek P, Gard B, Jensen JT, Edelman AB. Opioid Analgesia in Medication Abortion: A Randomized Control Trial. Obstet Gynecol 2019 Dec;134(6):1163-1170.

Danco: FDA Package Label; Current Mifeprex materials March 2016.

Dzuba IG, Castillo PW, et al. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. 2020 May. Contraception. 2020;S0010-7824(20)30160-8.

Dzuba I, Chong E, Hannum C, et al. Outpatient mifepristone-misoprostol medical abortion through 77 days of gestation. 2016 Oct;94(4):389.

Dzuba IG, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. Contraception. 2020 May;101(5):302-308.

Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195.

Fjerstad M, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception. 2011 Apr;83(4):330-5.

Gatter M, Cleland K, Nucatola DL, Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015 April 91(4): 269-73.

Grossman D, Grindlay K. Alternatives to Ultrasound for Follow-up After Medication Abortion: A Systemic Review. Contraception. 2011; 83(6):504–510.

Grossman D, et al. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011 Aug;118(2 Pt 1):296-303.

Grossman D, et al. Continuing pregnancy after mifepristone “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015 Sep;92(3):206-11.

Gynuity Health Projects. Consensus Statement: Instructions for Use: Abortion Induction with Misoprostol Alone in Pregnancies Through 9 Weeks’ LMP. October 2013.

Hamoda H, Ashok PW, Flett GM, Templeton A. Medical Abortion at 64 to 91 days of gestation: a Review of 483 Consecutive Cases. Am J Obstet Gynecol. 2003 May;188(5):1315-9.

Hamoda H, Ashok PW, Flett GM, Templeton Al. A Randomised Controlled Trial of Mifepristone in Combination with Misoprostol Administered Sublingually or Vaginally for Medical Abortion up to 13 Weeks gestation. BJOG. 2005 Aug;112(8):1102-8.

Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age. Contraception. 2019 Aug;100(2):142-146.

Horvath S, et al. The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization. Contraception 2020.

Hsia JK, Lohr PA, Taylor J, Creinin MD. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days’ gestation. Contraception. 2019;100(3):178-81.

Ipas Clinical Updates in Reproductive Health: Recommendations for abortion before 13 weeks gestation, Medication abortion. Published 2020.

Jones RK, WitwerE, Jerman J. Abortion Incidence and Service Availability in the United States, 2017. New York: Guttmacher Institute, 2019.

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medication Abortion in the Late First Trimester: A Systematic Review. Contraception. 2019 Feb;99(2):77-86.

Kavanaugh M, et al. Patients’ attitudes and experiences related to receiving contraception during abortion care.  Contraception. 2011; 84; 583-593.

Kulier R, Kapp N, Gulmezoglu A M, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD002855.

Larsson A, Rönnberg AM. Expanding a woman’s options to include home use of misoprostol for medical abortion up until 76 days: an observational study of efficacy and safety. Acta Obstet Gynecol Scand. 2019; 98747-752.

Lokeland M, Iverson OE, Dahle GS, Nappen MH, Ertzeid L, Bjorge L. Medical abortion at 63 to 90 days of gestation. Obstetrics & Gynecology. 2010 May;115(2), 962-968.

Matulich M, et al. Understanding women’s desires for contraceptive counseling at the time of first-trimester surgical abortion. Contraception. 2014; 89; 36-41.

Mark A, Foster A, Grossman D, et al. Forgoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee. Contraception. 2019 May;99(5):265-266.

Meites E, Zane S, Gould C; C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 2010 Sep 30;363(14):1382-3. 

Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and misoprostol for abortion through 56 days of LMP. Contraception 2005;72:328-332.

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to Mifepristone for Early Medical Abortion. Int J Gynaecol Obstet. 2007 Mar;96(3):212-8.

Murtagh C et al. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. Contraception. 2017; 92: 297-301.

National Abortion Federation Clinical Policy Guidelines 2020.

Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet. 2015 Feb 21;385(9969):698-704.

Perriera LK.  Reeves MF, Chen BA, Hohmann HL, Hayes J, Creinin MD. Feasibility of telephone follow-up after medical abortion. Contraception 2010; 81: 143-149.

Pocius KD, et al. Serum human chorionic gonadotropin (hCG) trend within the first few days after medication abortion: a prospective study. Contraception. 2016 Mar; 95 (3): 263-68.

Raymond E, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception. 2019;100:173-177.

Raymond EG, et al. No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond. Contraception. 2020 Apr; epub ahead of print.

Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr;97(4):292-296.

Raymond EG, et al. Effects of DMPA Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: An RCT. Obstet Gynecol. 2016 Oct;128(4):739-45.

Raymond EG, Weaver MA, Tan YL, et al. Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial. Obstet Gynecol. 2016 Feb;127(2):306-12.

Reeves MF, et al. Endometrial Thickness Following Medical Abortion Is not Predictive of Subsequent Surgical Intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-9.

Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008 Oct;78(4):332-5.

Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception. 2016 Feb;93(2):119-25.

Sääv I, et al. Early versus delayed insertion of intrauterine contraception after medical abortion – a randomized controlled trial. PLoS One. 2012;7(11):e48948.

Sanhueza Smith P, Peña M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82.

Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S.  Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.  Contraception 1999 Jan;59(1):1-6.

Schaff EA, et al.  Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002 Oct;66(4):247-250.

Schmidt-Hansen M, et al. Follow-up Strategies to Confirm the Success of Medical Abortion of Pregnancies Up to 10 Weeks’ Gestation: A systematic Review with Meta-Analysis. Am J Obstet Gynecol. 2019 Nov 9. pii: S0002-9378(19)32615-8.

Schonberg D, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90:480-7.

Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006 Feb;107(2 Pt 1):399-413. Review. Erratum in: Obstet Gynecol. 2006 Apr;107(4):955.

SFP ACOG Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-692.

Sheldon WR, Durocher J, Dzuba IG, Sayette H, Martin R, Velasco MC, Winikoff B. Early Abortion with Buccal vs Sublingual Misoprostol Alone: a Multicenter Randomized Trial. Contraception. 2019 May;99(5):272-277.

Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 89(3) 2014, pp. 148–161.

Stillman M, et al. Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open. 2020;10:e034670.

Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003 Nov;18(11):2315-8.

Tang OS, Xu J, Cheng L, Lee SW, Ho PC. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. Hum Reprod. 2002;17:99–102.

Von Hertzen H, et al. Misoprostol dose and route after mifepristone for early medication abortion: a randomized controlled noninferiority trial. BJOG. 2010 Aug; 117:1186-1196.

Von Hertzen H, Piaggio G, Huong NT, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled trial. Lancet. Jun 9 2007;369(9577):1938-1946.

Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012 Nov;120(5):1070-6.

World Health Organization. Medical Management of Abortion. Geneva, 2018.


EARLY ABORTION TRAINING CURRICULUM Copyright © 2020 by UCSF Bixby Center for Global Reproductive Health. All Rights Reserved.